(Q38142315)

29 August 2017

title

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy (English)

1 reference

29 August 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Anders Elm Pedersen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Caroline B Madsen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

publication date

24 September 2013

1 reference

Immunopharmacology and Immunotoxicology

29 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

649-652

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

Mucins in cancer: function, prognosis and therapy

14 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Structure and biology of a carcinoma-associated mucin, MUC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Mucin-type O-glycosylation and its potential use in drug and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Mucins in cancer: protection and control of the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

O-glycosylation of the mucin type

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Lectins identify glycan biomarkers on glioblastoma-derived cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

PankoMab: a potent new generation anti-tumour MUC1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Interferon-gamma upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Artificial T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Seromic profiling of colorectal cancer patients with novel glycopeptide microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08923973.2013.837060

10.3109/08923973.2013.837060

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24063621%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

1 reference